Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

137.52 -0.12 (-0.09%)
Streaming Delayed Price Updated: 11:53 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
1 Unprofitable Stock with Promising Prospects and 2 Facing Headwinds
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
Topics Artificial Intelligence
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
Jazz Pharmaceuticals trades at $138.50 and has moved in lockstep with the market. Its shares have returned 27.1% over the last six months while the S&P 500 has gained 22.9%. 
Via StockStory
Topics Government Stocks World Trade
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled. 
Via Benzinga
Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for... 
Via MarketMinute
Topics Intellectual Property
Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor
Via Stocktwits
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street
 
Via Benzinga
3 Cash-Producing Stocks We Approach with Caution
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
SciSparc And AutoMax Call Off Merger
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation. 
Via Benzinga
FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape
In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca... 
Via MarketMinute
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Jazz Pharmaceuticals Stock
 
Via Benzinga
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was... 
Via StockStory
Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 4.8% in the afternoon session after the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for... 
Via StockStory
Topics Artificial Intelligence
Jazz (JAZZ) Q2 Revenue Rises 2%
Via The Motley Fool
Topics Intellectual Property
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Recognized as a Decent Value Stock with Strong Fundamentals
Jazz Pharmaceuticals (JAZZ) is a value stock with strong fundamentals, trading below industry averages in P/E and EV/EBITDA, while maintaining high profitability and steady growth potential. 
Via Chartmill
Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Q2 In Line With Expectations But Stock Drops
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was... 
Via StockStory
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Reports Q2 2025 Earnings Miss and Leadership Transition
Jazz Pharmaceuticals Q2 2025 results miss revenue and EPS estimates, shares drop 6%. New CEO Renee Gala takes helm amid Xywav growth but investor concerns linger. 
Via Chartmill
Topics Earnings
Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings this Tuesday after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Via The Motley Fool
Where Jazz Pharmaceuticals Stands With Analysts
 
Via Benzinga
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
JAZZ Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and decent growth, making it a candidate for value investors. Check the full analysis for details. 
Via Chartmill
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options 
Via Benzinga
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
JAZZ Pharmaceuticals (NASDAQ:JAZZ) is an undervalued biopharma stock with strong profitability, reasonable financial health, and steady growth, making it a candidate for value investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.